Pelagos Pharmaceuticals, Inc.
Wednesday, June 05, 2024
Cardiovascular
Company Presentation Theater 3
Pelagos is a pre-clinical biotech company developing exercise mimetic drugs for diseases of aging. We have 2 small molecule programs targeting previously undrugged nuclear receptors, ERR and REV-ERB, to regulate cellular energetics, mitochondrial biogenesis, and inflammation and increase muscle function and exercise tolerance. Initial indications are heart failure (HFpEF and HFrEF) and obesity with muscle preservation.
Company Website:
http://www.pelagospharma.com
Lead Product in Development:
P109: Rev-Erb Agonist for Heart Failure
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Houston
Company HQ State
Texas
Company HQ Country
United States
CEO/Top Company Official
Dan Watkins
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())